Viking Therapeutics, Inc.VKTX

時価総額

$38.5億

PER

臨床段階のバイオ医薬品開発の新興企業。GLP-1作動薬やDACRAを含む肥満・代謝疾患向け候補薬を開発。2023年4月の公募で純収入2.70億ドル、2024年3月の公募で純収入5.97億ドルを調達。米国サンディエゴ拠点。

	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-	-	-	-22	-26	-39	-55	-69	-86	-110
(Accretion) amortization of investment premiums	-	-	-	-	-	-	-	-	8	17
Amortization of financing costs	-	138,701	571,044	0	0	0	0	0	0	0
Stock-based compensation	3	2	1	3	4	6	6	9	17	30
Amortization of right-of-use assets	-	-	-	-	-	-	-	0	0	0
Realized gain on investment	-	-	-	-	-	-	-	-	-	0
Operating Leases Interest Expense	-	-	-	-	0	0	0	0	0	0
Prepaid expenses and other current assets	1	-273,329	-497,626	0	7	-0	1	3	-6	-0
Accrued interest, net of interest receivable on maturity of investments	-	-	-	-	-	-3	-1	-1	-0	-1
Accounts payable	219,237	677,185	263,509	-1	1	2	-3	7	-1	2
Accrued expenses	2	-141,295	1	1	2	4	-1	6	-2	6
Lease liability	-	-	-	-	-0	-0	-0	-0	-0	-0
Net cash used in operating activities	-	-	-	-19	-25	-22	-48	-48	-73	-88
Purchases of investments	16	17	23	348	362	281	168	121	478	1,113
Proceeds from sales and maturities of investments	3	20	21	82	370	322	206	176	299	560
Net cash (used in) provided by investing activities	-	-	-	-266	7	42	38	55	-179	-553
Public offering, net of offering costs	-	-	-	-	-	-	-	-	-270	-597
Value of shares withheld related to employee tax withholding	418,412	31,061	21,712	0	0	0	1	2	7	42
Repurchase of common stock	38	229	-	-	-	-	-	7	-	-
Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan	-	-	-	-	-	-	-	1	7	11
ATM offering, net of fees	-	-	-	-	-	-	-	12	2	47
Net cash provided by financing activities	-	-	-	300	1	1	7	4	271	612
Net (decrease) increase in cash and cash equivalents	-	-	-	-	-	-	-	-	19	-29
Effect of exchange rate changes on cash	-	-	-	-	-	-	-	-0	-0	-0
Unpaid deferred public offering and other financing costs	-	-	139,585	-	0	0	0	0	0	0
Right-of-use asset obtained in exchange for lease obligation	-	-	-	-	-	-	-	2	-	0